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Human cytomegalovirus (HCMV)' is a human herpesvirus that establishes
lifelongpersistent infection, after an often asymptomatic primary infection. Persis-
tent infection may reactivate and become clinically evident after immunosuppres-
sion, resulting in significantmorbidity and mortality (1). Reactivation in the context
ofimmunosuppression suggests that virus-specific Tcells, including HCMVspecific
CTL, playamajor role in maintaining thenormal virus-host equilibrium. We have
previously reported that MHC class I-restricted, CD8+ , HCMVspecific CTL
precursors (CTLp) are present in PBLofasymptomatic, persistently HCMVinfected
individuals (2). These CTL arepresent at aprecursor frequency of1/5,000-20,000
PBL, higher than that of varicella zoster virus (VZV)-specific CTL (3). Further-
more, HCMVspecificCTL killed virus-infected cells before viral DNA replication,
suggesting that they recognized predominantly nonstructural viral proteins (2-4).
However, by limiting dilution analysis a minor population ofCTL were identified
that only killed HCMVinfected target cells expressing late (structural) viral pro-
teins (3). In murine cytomegalovirus (MCMV) infection, which is similar in some
respects to HCMV infection, MCMVspecific CTL mayprotect againstvirusinfec-
tion (5). These protective CTL are specific for viral immediate early (IE) proteins,
the first, nonstructural viral proteins expressed in the infected cell (6).
After HCMV infection ofdiploid human fibroblasts, the only cells fully permis-
sive for HCMV replication in vitro, there is a regulated expression ofvirus gene
products (1). Within 4-6 h of infection, viral IE genes are expressed. They code
for four to five predominantly intranuclear proteins, the most abundant of which
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is a 72-kD protein (7, 8). These proteins positively trans-regulate expression of the
early (E) viral genes (7-9), and negatively autoregulate their own expression (10).
The E genes encode a number of proteins, including the viral DNA polymerase,
essential for HCMV DNA replication that occurs N18 h after infection; only then
are the 30-33 late (L) genes, coding mainly for the structural proteins ofthe virion,
expressed.
The size of the HCMV genome (235 kbp) allows for a large potential coding ca-
pacity (1), and thus there are obvious difficulties in determining whether individual
viral proteins are immunodominant with respect to the CTL response. The specificity
of CTL for particular stages of virus gene expression can be examined using meta-
bolic inhibitors, such as phosphonoformate (PPF) (3, 4), to prevent expression of
L genes. However, positive identification of viral determinants recognized by CTL
can best be achieved by using expression vectors that permit expression of single
HCMV genes .
In the case of human persistent virus infections, there is little information on the
relative preponderance of CTL specific for individual or stage-specific virus gene
products. In these studies we have examined HCMVspecific CTL using recom-
binant vaccinia viruses that encode the HCMV structural glycoprotein B (vac.gB)
(11) and the 72-kD IE protein (vac.IE) . This approach was combined with limiting
dilution culture, which permitted both a quantitative and clonal analysis of the CTL
response to these viral proteins. Both vac.gB- and vac.IE-infected cells were recog-
nized by HCMVspecific CTL. The frequency of IE protein-specific CTL was be-
tween 18 and 58% of HCMVspecific CTLp in the two subjects studied (n = 138/21
and 77, respectively), compared with 0-20 /o and 6% for gB. These results suggest
that the 72-kD IE protein is recognized by a large proportion of HCMVspecific
CTL in the asymptomatic persistently HCMVinfected individual.
Materials and Methods
Cells and Viruses.
￿
HCMV strain AD169 (No. VR538; American Type Culture Collec-
tion, Rockville, MD) was grown in F5000 (Flow Laboratories, Inc., McLean, VA) diploid
human fibroblasts, innoculated at a multiplicity of infection (MOI) of 0.1:1 . Supernatant
virus was harvested, plaqued on F5000 cells, and virus stocks with a titer >10' plaque-
forming units (PFU)/ml were stored at -70°C until use. Vaccinia WR strain (vac.WR) was
grown in Vero cells and supernatant virus was harvested, plaqued (titer 109), and stored in
1-ml aliquots at -70°C. VZV and HSV were propagated as previously described (3).
Primary human fibroblastlineswere established by explant cultures as previously described
(2), from individuals of known HLA type. These cells and F5000 cells were maintained in
MEM supplemented with 1017o FCS, 2 MM L-glutamine, 100,000 IU/literpenicillin, 10 mg/liter
streptomycin, and 1% nonessential amino acids (Gibco Laboratories, Grand Island, NY).
Fibroblasts, free of mycoplasma contamination by DNA staining and culture, and between
passage 10-20, were used in these experiments.
Recombinant Vaccinia Viruses.
￿
Vac.gB encoding HCMV gB was constructed as previously
described (11). Vero cells, diploid human fibroblasts, and EBVtransformed B cells infected
with vac.gB expressed gB, as detected by a mAb (provided by H. Hart, Inveresk Research
International, Edinburgh, Scotland [111), in a cytoplasmic distribution, with some weak nu-
clear membrane fluorescence, again as previously described (11).
Vac.IE was constructed from the cDNA clone (pJD083) of the IE gene encoding the 72-
kD IE protein of HCMV strain AD169, inserted into the Pst I site of pUC9 (provided by
J . Oram, Public Health Laboratory Service, Centre for Applied Microbiology & Research,
Porton Down, UK) (12) (Fig. 1). A 1.7-kb Eco RI-Hind III fragment containing the com-Smal
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Construction of the vac.1E recom-
binant from the cDNA ofthe HCMV AD169 72-
kD IE protein in pJD083 (see text for details).
plete major IE coding region was gel purified and blunt ended with Klenow fragment. The
fragment was ligated into the unique Sma I site of the coinsertion vector pSC11 (13), down-
stream of the vaccinia early promoter (p7 .5). Correct insertion and orientation ofthe reading
frame were confirmed by diagnostic restriction enzyme digestion and agarose gel elec-
trophoresis.
Transfection and coinfection with vacWR ofCV1 cells was performed according to estab-
lished methods (14). TK- progeny virus was selected using BUdR (50 pg/ml). TK- recom-
binants were distinguished from spontaneous TK- mutants, by overlaying with 1% agarose
containing 0.1% neutral red and 300 wg/ml Xgal (5-bromo-4-chloro-3-indoyl-a-n-
galactopyranoside) to screen for a-galactosidase activity (13). Plaques giving an intense blue
colour after4-6h were selected, further plaque purified and recombinant virus stocks grown
in CV1 cells (14).
The recombinant virus genome was analyzed by restriction endonuclease digestion and
Southern blotting (data not shown) which confirmed that the HCMV major IE gene had
been inserted into the vaccinia TK gene with no other genomic alterations.
Generation of HCMV-speck and gB-specific CTL.
￿
PBL from HCMVseropositive subjects
were stimulated by cocultivation with autologous fibroblasts (responder/stimulator - 50:1),
infected with either HCMV for 48 h or recombinant vaccinia virus for 12 h, then UV inacti-
vated in 24-well plates (Linbro; Flow Laboratories, Inc.), for 5 d in RPMI supplemented
as for MEM but with 10% HCMVseronegative AB serum. The medium was then changed
and 2/IU/ml rIL-2 (Boerrhinger Mannheim Biochemicals, Indianapolis, IN) added. Stimu-
lator cells with irradiated autologous PBL (2,500 rad) were added at 7 d, and the cells were
allowed to grow for a further 7 d in rIL-2. Viable cells were harvested by Ficoll/Hypaque
density centrifugation and assayed in "Cr-release assays (2) as indicated in the text.
Limiting Dilution Cultures.
￿
Limiting dilution cultures to estimate the precursor frequency
and analyze the clonal specificity of HCMVspecific CTL were performed as described (3).
Briefly, PBL or E' cells isolated from PBL by rosetting with AETtreated SRBC (15) were
used. Between 100 and 10,000 lymphocytes were placed in 96-well round-bottomed plates
(Linbro; Flow Laboratories, Inc.) in 30-120 replicate cultures at each input cell concentra-
tion. These were divided between several plates to overcome plate-to-plate variation. 2 x
103 48-h HCMVinfected autologous fibroblasts, together with autologous irradiated PBL922
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to a final cell concentration of 105 cells/well, were added and the cultures were incubated
in RPMI with 10% AB serum supplemented with 2 IU/ml rIL-2 .
The cultures were refed at 3-d intervals for 11-14 d. Identical cultures were also established
with irradiated (2,500 rad) PBL as feeder cell controls.
The cultures were then equally divided and cytotoxicity was determined against four to
six different target cells as described in individual experiments. For each target cell, max-
imum and spontaneous release values between plates were compared for interplate variation
by one-way analysis of variance using the Scheffe multiple comparison test (16). Each test
well was compared with the "feeder cell only" controls and significant 5'Cr release was de-
termined if the counts were >3 SD above the release observed in the control wells (3). Each
well was scored by the different target cells lysed. Virus-specific, MHC-restricted lysis was
observed when the effector cells from an individual well lysed the autologous virus-infected
cells and target cells in the presence oflectin, but not HLA-mismatched virus-infected cells,
or autologous cells infected with an irrelevant virus.
The best straight line fit comparing the logo of the proportion of negative wells against
the input cell number was determined by the method of least squares, and the linearity was
further examined by regression analysis (3, 16, 17). From these estimates the frequency of
specific CTLp could be estimated as the input cell number that would produce 37 % negative
cultures against a particular target(s) (17). All statistical analysis was performed using
SPSS/PC + (SPSS Inc., Chicago, IL) (16).
Other Reagents.
￿
mAbs L14 (kindly provided byJ . A. Nelson and M. B. A. Oldstone, Scripps
Clinic and Research Institute, LaJolla, CA) (18) and Cll (provided by Dr. G. The, University
of Gronigen, The Netherlands) against the 72 kD major IE protein of HCMV were used
for indirect immunofluorescence offixed and permeabilized infected monolayersof cells (19).
Results
Expression of 72-kDMajor IE Protein in Cells Infected with vac. IE.
￿
Two mAbs specific
for the HCMV 72-kD IE protein, L14 and C11, were used to confirm its expression
by indirect immunofluorescence. Monolayers of Vero cells and human fibroblasts
infected for 12 h at 10 PFU/cell with vac.IE or vacWR, were fixed and permeabi-
lized (19), and then stained with L14 or Cll and (Fab)2, rabbit anti-mouse Ig-FITC
(Dako) (Fig. 2). Vac.IE-infected cells had positive nuclear fluorescence, detectable
as early as 4 h after infection, increasing up to 12 h. There was no fluorescence in
vacWRinfected cells. On Western blot analysis a protein of 71-73 kD was detected
in HCMV or vac.IE-infected cell lysates, using Cll, although not with L14 (data
not shown).
HCMV-specific CTL Recognize the 72-kD IE Protein and gB.
￿
To determine if the
HCMV 72-kD IE protein and gB were recognized by HCMVspecific CTL, PBL
from seropositive and seronegative subjects were coculturedwith 48-h HCMVinfected
autologous fibroblasts under limiting dilution conditions, as described in Materials
and Methods. After 11 d individual wells were assayed against HCMVinfected au-
tologous and HLA-mismatched fibroblasts to determine the frequency of all HCMV
specific CTL (3). HCMVspecific CTL in subject CH were present at a frequency
of 1/11,000 (95% confidence limits: 1/5,000-1/17,000) (Fig. 3). In addition, each in-
dividual well was assayed against autologous and HLA-mismatched B cell lines in-
fected with the vaccinia recombinants. HCMV 72-kD IE protein-specific CTL were
present at 1/76,000 PBL (1/36,000-116,000). In the same experiment, HCMV
gB-specific CTL were present at the limits of the assay at 1/181,000 PBL. There
was no specific lysis of vacWRinfected target cells. No HCMV, HCMV 72-kD IE
protein, or HCMV gB-specific CTL were present in seronegative subjects .BORYSIEWICZ ET AL . 923
FIGURE 2 .
￿
Human primary fi-
broblasts infected with vac.IE ex-
pressed the 72-kD IE protein as
detected by mAbs . Fibroblasts
were infected for 12 h (MOI
10:1) with vac.IE (top) (x 200),
infected with vac.WR (middle)
(x 200), andHCMV for 24 h
(bottom) (x 400). The cells were
fixed in methanol/acetone, per-
meabilized, and stained by in-
direct immunofluorescence
usingmAbCll . vac.IE-infected
cells expressed the HCMV 72-
kD IE protein in nuclear distri-
bution .924
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TABLE I
Relative Numbers of vac.gB- and vac.IE-speck CTL Clones in
Asymptomatic HCMV-seropositive Subjects
FIGURE 3.
￿
Frequency analysis
of HCMV and vac.IE-specific
CTLp.PBLfrom aseropositive
subject(CH) were grownin lim-
iting dilution (120 replicate cul-
turesat each inputcell number),
with autologous HCMVinfect-
ed fibroblasts, irradiated PBL
and HL-2 . After 11 d the cul-
tureswere assayed against48-h
HCMVinfected autologous and
HLA-mismatched fibroblasts,
to determine the presence of
HCMVspecific CTL(/), and
against vac.IE- and vac.gB-in-
fected autologous and vac.IE-
infected, HLA-mismatched
EBVtransformed B cell lines, to
determine 72-kD IE-specific
CTL (*). Bars indicate 95%
confidence limits foreach input
cell number;hatchedarea indi-
cates 95% confidence interval
for the regression lines.
Relative Frequencies of HCMV 72-kD andgB-specific CTL Clones.
￿
The relative fre-
quencies ofclonallyderived (3, 17), vac.IE- andvac.gB-specific CTLwere compared,
together with the ability ofthe same clones to mediate lysis ofHCMV infected au-
tologous fibroblasts. The data are shown in Table 1. In three separate experiments
in two seropositive subjects (CH and AR), the frequency of vac.IE-specific CTL
Exp. Subject
Number of wells
vac.IE gB - -vac.
(percent of row total)
Other Total
1 CH
HCMV lysed 25 (18) 4 (2) 109 (80) 138
HCMV not lysed 4 (2) 0 (0) 138 (98) 142
Total 29 4 247 280
2 CH
HCMV lysed 9 (43) 0 (0) 12 (57) 21
HCMV not lysed 0 (0) o (0) 100 (100) 100
Total 9 0 112 121
3 AR
HCMV lysed 45 (58) 5 (6) 27 (36) 77
HCMV not lysed 16 (29) 0 (0) 40 (71) 56
Total 61 5 67 133BORYSIEWICZ ET AL.
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FIGURE 4. Vac.gB-infected fibroblasts activated HCMV-specific CTL in vitro. PBL from a
seropositive subject (AR), were cocultured with vac.gB-infected, UVinactivated, autologous fibro-
blasts as described in Materials and Methods. After 14 d, viable lymphocytes were assayed in
a"Cr-release assayagainst autologous, partially HLAA and B-matchedand HLA-mismatched
fibroblasts that were uninfected (") or infected with HCMV (L7), vac.gB (O), or vac.WR
Bars indicate + 1 SD.
clones was greater than vac.gB-specific clones. In the first and third studies, vac.IE-
specific CTL clones derivedfromthe different donors lysed HCMVinfected autolo-
gous fibroblasts and represented 18.1 and 58.4%, respectively, ofall wells mediating
HCMV-specific CTL lysis. However, inthese two experiments, although thevac.IE-
specific CTL were clonally derived, the cultures lysing HCMVinfected fibroblasts
were not by the standard criteria for limiting dilution analysis described by Lef-
kovitz and Waldeman (17).
When the experiment was repeated with cells from donor CH (Table 1, Exp. 2),
although fewerclones were studied, both cultures with HCMV-specific and vac.IE-
specific CTL activity were clonally derived and 43% of all HCMV-specific CTL
clones also lysed autologous vac.IE-infected cells.
Therewasno instance ofan individual wellkillingboth vac.IE- andvac.gB-infected
cells. However, asmall numberofvac.IE-specific CTLclones did notlyseautologous
HCMVinfected fibroblasts.
GenerationofHCMV-speck CTL with vac.IE.
￿
To determine whetherHCMV-specific
CTL could be generated using vac.IE, PBL were cocultured with UV-inactivated
vac.IE-infected autologous fibroblasts or EBVtransformed B cell lines. In five ex-
perimentsfrom three seropositive subjects no HCMV-specific CTL were generated,
although in two of the five studies, nonspecific cytotoxicity was observed.
Generation of HCMV-specific CTL with vac.gB.
￿
To determine whether HCMV
memory CTL could beactivated invitro bya single structural HCMV protein (gB)
expressed in vaccinia-infected cells, PBL were cocultured with cells infected with
vac.gB. Autologous fibroblasts were infected with vac.gB for 12 h, UV treated to
inactiveresidualand releasedvaccinia virus, and cocultured withPBLfromHCMV
seropositive and seronegative subjects. The cultures were restimulated with vac.gB-
infected cells after 7 d and the lymphocytes were allowed to grow in the presence
ofrIL-2 for a further week. Viable cells were then assayed against autologous, par-
tially HLA-matched and -mismatchedfibroblasts, uninfected or infected with HCMV
vacWR, and vac.gB. Onlyautologous andpartially HLA-matched cellsinfected with
the recombinant or HCMV were lysed by the effector cells from a seropositive sub-
ject (Fig. 4); there was no significant lysis by PBL from a seronegative subject.926 HUMAN CYTOMEGALOVIRUS-SPECIFIC CYTOTOXIC T CELLS
FIGURE 5.
￿
Limiting dilution analysis of
vac.gB-activated, HCMVspecific CTL.
1,000 to 20,000 E*PBL(subject AR)were
grownin 30 replicate cultures at each input
cell concentration, with 2,000 vac.gB-in-
fected, UVinactivated autologous fibro-
blasts, irradiated (2,500 rad) PBLandIL-2
for 12 d. Theindividual wellswere assayed
againstHCMVinfected (48 h) ("), vac.gB-
infected (12 h) (")autologous fibroblasts,
andK562 cells with PHA(/). No signifi-
cant lysis of uninfected or VZVinfected
autologous fibroblasts wasdetected (data
not shown). Precursor frequencies from
limiting dilution plot: HCMVspecific
CTL, 1/20,000; vac.gB-specific CTL,
1/16,000.
To analyze the frequency ofsuch CTLp the experiment was repeated under lim-
iting dilution conditions (Fig. 5). A similar frequency of CTL lysing vac.gB- and
HCMVinfected cells would be expected under these conditions, as only a single
HCMV protein was used to stimulatethe response. 1/20,000 E+ PBL lysed HCMV-
infected autologous fibroblasts and 1/16,000 lysed vac.gB-infected fibroblasts. Fur-
thermore, there was almost complete concordance when the lysis of HCMV and
vac.gB-infected cells by individual wells containing the progeny of a single cell, as
predicted from the limiting dilution plots, was compared (data not shown). In par-
allel experiments the HCMVspecific CTLp frequency, using autologous HCMV
infected fibroblasts as stimulator cells in limiting dilution cultures, was 1/5000
E+PBL (3).
Discussion
In this study we have shown, using vaccinia recombinants encoding the HCMV
72-kD IE protein and gB, that HCMVspecific CTL from individuals persistently
infected with HCMV recognized these viral proteins. The relative number ofHCMV
72-kD IE protein-specific CTL in PBL was much greater than gB-specific CTL in
the subjects studied. HCMVspecificmemory CTL were activated bycoculturewith
vac.gB-, but not vac.IE-infected fibroblasts. These results suggest that whereas some
CTL specific forHCMV structural proteins, such as gB, are present in PBL, acon-
siderably greater proportion ofHCMVspecific CTL recognize a nonstructural pro-
tein, the 72-kD IE protein.
We have previously shown that HCMVspecific CTLp were present in PBL of
normal clinically asymptomatic HCMV seropositive individuals (2) and at a rela-
tively high frequency (3). In addition, the majority ofHCMVspecific CTL clonesBORYSIEWICZ ET AL.
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recognized target cells thatexpressed only the nonstructuralIE and Eproteins. How-
ever, these results also showed that a small number ofCTL clones lysed HCMV
infected target cellsexpressing L proteins only (3). To furtheridentifywhich HCMV
proteins were recognized by CTL, we decided to express individual HCMV genes
in target cells for use in cytotoxicity assays. Initial attempts were made to achieve
this bydirect transfection with aplasmid (pES) encoding the HCMVAD169 72-kD
IE protein (20), but<10% ofcellsexpressed the HCMVprotein and then onlytran-
siently (<10 /o ofcells after 48 h). We therefore used vaccinia recombinants encoding
single HCMV genes to increase the number of target cells expressing the inserted
HCMV gene.
Vaccinia recombinants have recently been used to identify a number ofviral de-
terminants recognized by human CTL, including influenza nucleoprotein (21), RSV
nucleoprotein (22), HSV glycoproteins (23), and HIV glycoprotein (24). Most of
the viral antigens recognized by virus-specific CTL, which have been identified to
date, are intranuclear/intracellular viralproteins, but viral glycoprotein-specific CTL
have also been described (23-25). There has been no previous study to determine
the relative frequency of MHC class I-restricted CTL specific for different virus
gene products during persistent herpesvirus infection in man.
Many HCMVspecific CTL present in PBL recognized vac.IE-infected autolo-
gous B cell lines and fibroblasts. Two subjects were investigated in detail; extrapola-
tionfromthis informationto an outbredheterogenous population mustbe guarded,
particularly as the specificity of many ofthe CTL clones (subject CH) remains to
be identified and it is possible that specificity may vary with HLA haplotype, as
in the case of influenza (21). However, the high frequency of CTLp in peripheral
blood directed against a single viral protein suggests that the 72-kD IE protein is
an important recognition element for HCMVspecificCTL during persistent infec-
tion. The CTL response against HCMV and other human herpesviruses may be
important in maintainingthevirus/hostequilibrium. The HCMV IEgene encoding
the 491-amino acid, 72-kD protein consists of four exons, and although its exact
role is unknown, it is among the first HCMV genes transcribed. Its expression is
essential for virus replication (1, 7-10, 12), and thus the ability ofCTL to lyse cells
expressing this intranuclearviralprotein may permit the early recognition and limi-
tation oflocal HCMV reactivation, even before virus replication. It should also be
noted that certainly in vitro, and possibly in vivo, some cell types only express IE
genes, with an apparent block to later HCMV gene expression. It is reported that
IE mRNA canbe detected in small fraction (<0.01%) ofhuman PBMC during per-
sistent infection (26). It may be that such expression ofIE genes provides selective
restimulation in vivo and contributes to the relatively high frequency of72-kD IE-
specific CTLp.
From previous studies we identified a subpopulation ofMHC class I-restricted,
HCMVspecific CTL that recognized structural or L viral proteins (3). Vac.gB (11)
was used to determine ifmemory CTL could be activated by and recognize vac.gB-
infected cells. The gene for gB was originally identified within the HCMV AD169
genome, in the Hind HIT fragment, and it encodes a 906-amino acid protein that
is present in HCMVinfected cells in two major glycosylated forms of 144 and 55
kD. It shares homology with HSV gB, EBV gB, and VZV gpII, is expressed in in-
fected cells and HCMV virions, and antibodies to gB neutralize HCMV infectivity928
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(11). We found that HCMV gB-specific CTL were present in PBL and could be
activated in vitro using the vaccinia recombinant to lyse HLA-matched HCMV
infected fibroblasts. Although HCMV gB-specific CTL were activated using this
protocol, no vaccinia-specific CTL were generated, even when PBL from revacci-
nated subjects were used, either in bulk or limiting dilution culture (Graham, S.,
and L. K. Borysiewicz, submitted for publication).
Although gB-specific CTL were activated in vitro by vac.gB, no 72-kD IE pro-
tein-specific CTL have been generated using vac.IE-infected autologous fibroblasts
or EBVtransformed B cell lines as stimulator cells. The majority of PBL prolifer-
ating in such cultures were CD4+ and, only non-MHC-restricted lysis was ob-
served. There are several possible explanations for this descrepancy, but generation
of CTL by vac.gB in vitro seems to be an exception to the general rule that it is
difficult to use recombinant vaccinia viruses for secondary in vitro stimulation, not
least because of the need to prevent spread of vaccinia in the culture.
A further point requiring explanation is the observation that when B cell lines
infected with vac.IErecombinants were usedas target cells inlimitingdilution assays,
a small proportion ofthe vac.IE-specific CTLp lysedthesebut not autologous HCMV
infected fibroblasts. One possible explanationforthiswouldbethepresence ofHCMV
specific MHC class II-restricted CTL (27) in these cultures, preferentially killing
the B cell targets.
Evidence for any protective role for HCMVspecific CTL in man must ofneces-
sitybeindirect, drawn from clinical correlations (28)andrepresentative animal models.
In this context, MCMV infection, although MCMV is distinct from HCMV by
DNA hybridization, displays some similarities with the biology of HCMV infec-
tion. Reddehase et al. (29, 30) have examined the CTL response in BALB/c mice
after MCMV infection. Afterprimary footpad innoculation, two stage-specific sub-
populations ofCTL arepresent in draininglymphnodes, recognizing MCMV IEA
and "viral late membrane proteins" (inferred to be glycoproteins as the target cells
were prepared by infection at high multiplicity in vitro, with UV-irradiated virus
that would not permit de novo viral protein synthesis). In persistently infected mice
both subpopulations are detected, but only after secondary in vitro stimulation. A
MCMV 89-kD IE-specific CTL clone hasbeenestablished and maintained in vitro
(31, 32), and although this clone is not itself protective, mixed populations of Lyt-
2+ , IEA-specific CTL protect against lethal infection in irradiated mice (5, 6).
Usingdeletions ofthe MCMV 89-kD IE gene invaccinia recombinants, the region
ofthe protein recognized by the CTL clone was identified and protection after vac-
cination with the deleted recombinant was demonstrated, although in surviving
animals persistent MCMV infection was not prevented (33).
Our observations concerning the high frequency of HCMV nonstructural pro-
tein, and more particularly, 72-kD IE protein-specific CTLp, accord well with the
studies of MCMVspecific CTL (5, 6, 29-33), and it is possible that CTL ofthis
specificity mayprovide animportanthostdefencemechanism againstHCMV reac-
tivation . However, it remains difficult to directly extrapolate from MCMV studies
to man; for instance, the possibility exists that as with other virus infections, CTL
may also be implicated in immunopathological injury (34, 35).
It has been shown that human and murine influenza-specific CTL recognize
processed linear peptides of predominantly, but not exclusively, intracellular viralBORYSIEWICZ ET AL.
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proteins associated with MHC class I molecules (36), and that different peptide or
viralprotein specificities maypredominate, dependingon the MHC haplotype (21).
We intend to use vaccinia recombinants encoding differentHCMV proteins to identify
otherpossible CTLdeterminants and to usedeletionswithin thegene forthe 72-kD
IE proteinto define the CTLepitope(s) important forrecognition. A further advan-
tage of vaccinia recombinants as regards HCMV is that their wider host cell range
in vitro enables cells other than fibroblasts, notablyB cell lines, to be used as target
cells. This should permit investigation ofthe role ofMHC class II-restricted HCMV
specific CTL, and CTL responses in larger numbers of subjects particularly those
at risk of.HCMV disease, something that has previously been difficult because of
the requirement for primary fibroblast lines.
In this study we have identified the virus gene products recognized by a propor-
tion of the human, MHC class I-restricted HCMVspecific CTL during persistent
virus infection. This has been achieved by coupling theuse ofvaccinia recombinants
encoding a major IE gene and an important structural viral glycoprotein that has
neutralizing epitopes, with limiting dilution analysis of the CTL response. Further
studies will be aimed at better defining the specificity and role of CTL in HCMV
infection. Such information would contribute to a logical approach to HCMV pro-
phylaxis and enhancingspecific CTL in individuals at high risk of HCMV reactiva-
tion. In particular, the use of a combination subunit vaccine encoding both a virus
glycoprotein and IE protein(s), with the aim of stimulating the generation of neu-
tralizing antibody and protective virus-specific CTL, might warrant consideration.
Summary
CTL are held to be an important host defense mechanism in persistent herpes-
virusinfections. We have thereforestudiedthe nature and specificity ofhumancyto-
megalovirus(HCMV)-specific CTL in normal persistently infected individuals. This
was achieved by usingvaccinia recombinants encoding viralgenesexpressed at different
stages of the virus replicative cycle, a structural glycoprotein gB (vac.gB) and the
major 72-kD immediate early nonstructural protein (vac.IE) ofHCMV, combined
with limiting dilution analysis of the CTL response. In two subjects, 43 and 58%
of HCMV CTL precursors (CTLp) lysed vac.IE-infected cells, in contrast to <6 17
lysing gB-infected cells. HCMVspecific CTL could also be generatedby secondary
in vitrostimulation with vac.gB- butnotvac.IE-infected autologous fibroblasts. The
high frequencyof 72-kD IE protein-specific CTL suggests that this is at least amajor
recognition element for the HCMVspecific CTL response in asymptomatic persis-
tently infected individuals, and CTL with this specificity may be important in main-
taining the normal virus/host equilbrium.
We are indebted to Dr. J. D. Oram for providing the HCMV 72-kD IE cDNA clone. We
would also like to thankDr. J. L. Geelan forthepES plasmid andDrs. J. A. Nelson, M. B. A.
Oldstone, G. The, and H. Hart for making their mAbs available to us.
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